Role of deferoxamine in tumor therapy

A. Donfrancesco, G. Deb, L. De Sio, R. Cozza, A. Castellano

Research output: Contribution to journalArticlepeer-review


Several studies are consistent with the hypothesis that available iron may have some role in promoting tumor cell growth with different biological mechanisms. For this reason, several studies have been carried out to demonstrate the antitumor activity of deferoxamine (DFO), an iron chelator with a high affinity for ferritin-bound iron. In particular, the effects of DFO have been studied in patients with neuroblastoma, where ferritin is in part tumor derived and high concentrations correlate with poor outcome. To date, in vitro and in vivo studies demonstrating the antitumor effects of DFO are very promising, but further investigations are required to establish an exact role for DFO in the treatment of cancer.

Original languageEnglish
Pages (from-to)66-69
Number of pages4
JournalActa Haematologica
Issue number1
Publication statusPublished - Feb 1996


  • Deferoxamine
  • Iron
  • Neuroblastoma
  • Tumor therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Role of deferoxamine in tumor therapy'. Together they form a unique fingerprint.

Cite this